These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 26708016)
21. Sorting and gene mutation verification of circulating tumor cells of lung cancer with epidermal growth factor receptor peptide lipid magnetic spheres. Wang SG; Zhang B; Li CG; Zhu JQ; Sun BS; Wang CL Thorac Cancer; 2020 Oct; 11(10):2887-2895. PubMed ID: 32856417 [TBL] [Abstract][Full Text] [Related]
22. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318 [TBL] [Abstract][Full Text] [Related]
23. A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. Lim M; Park J; Lowe AC; Jeong HO; Lee S; Park HC; Lee K; Kim GH; Kim MH; Cho YK Theranostics; 2020; 10(12):5181-5194. PubMed ID: 32373206 [No Abstract] [Full Text] [Related]
24. Challenges in circulating tumor cell detection by the CellSearch system. Andree KC; van Dalum G; Terstappen LW Mol Oncol; 2016 Mar; 10(3):395-407. PubMed ID: 26795350 [TBL] [Abstract][Full Text] [Related]
26. Single tube liquid biopsy for advanced non-small cell lung cancer. de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653 [TBL] [Abstract][Full Text] [Related]
27. Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. D'Oronzo S; Lovero D; Palmirotta R; Stucci LS; Tucci M; Felici C; Cascardi E; Giardina C; Cafforio P; Silvestris F Sci Rep; 2019 Nov; 9(1):17276. PubMed ID: 31754145 [TBL] [Abstract][Full Text] [Related]
28. The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment. Wei T; Zhu D; Yang Y; Yuan G; Xie H; Shen R PLoS One; 2019; 14(7):e0219129. PubMed ID: 31344053 [TBL] [Abstract][Full Text] [Related]
30. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689 [TBL] [Abstract][Full Text] [Related]
31. [Preliminary Study on Detection of Circulating Tumor Cells in Lung Cancer by EGFR/Vimentin/Folic Acid Magnetic Sphere]. Li G; Wang Y; Tan G; Liu Y; Xu Z; Feng H; Xing W; Xu Z Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):351-359. PubMed ID: 32336066 [TBL] [Abstract][Full Text] [Related]
32. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222 [TBL] [Abstract][Full Text] [Related]
33. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588 [TBL] [Abstract][Full Text] [Related]
34. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882 [TBL] [Abstract][Full Text] [Related]
35. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases. Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084 [TBL] [Abstract][Full Text] [Related]
36. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Premasekharan G; Gilbert E; Okimoto RA; Hamirani A; Lindquist KJ; Ngo VT; Roy R; Hough J; Edwards M; Paz R; Foye A; Sood R; Copren KA; Gubens M; Small EJ; Bivona TG; Collisson EA; Friedlander TW; Paris PL Cancer Lett; 2016 Sep; 380(1):144-52. PubMed ID: 27343980 [TBL] [Abstract][Full Text] [Related]
37. The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. de Wit S; van Dalum G; Lenferink AT; Tibbe AG; Hiltermann TJ; Groen HJ; van Rijn CJ; Terstappen LW Sci Rep; 2015 Jul; 5():12270. PubMed ID: 26184843 [TBL] [Abstract][Full Text] [Related]
38. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704 [TBL] [Abstract][Full Text] [Related]
39. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752 [TBL] [Abstract][Full Text] [Related]
40. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]